Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Moderate chronic kidney disease (CKD) affects over 8% of US adults and is an independent predictor of cardiovascular (CV) disease and mortality.
• Elevated intact parathyroid hormone (iPTH) is linked to CV mortality in end-stage renal disease, but its role in moderate CKD is less clear.

Purpose of the Study:

• To investigate the association between serum intact parathyroid hormone (iPTH) levels and cardiovascular (CV) events in patients with moderate (stages 3 and 4) chronic kidney disease (CKD).
• To determine if iPTH is an independent predictor of CV events in this patient population.

Main Methods:

• Retrospective review of medical records for 196 patients with stages 3-4 CKD (GFR 16-59 ml/min/1.73 m²).
• iPTH levels were measured between April 2006 and September 2007.
• Cardiovascular events included myocardial infarction, stroke, revascularization procedures, and CV-related death during a median follow-up of 27.2 months.

Main Results:

• Patients experiencing CV events had significantly higher iPTH levels (156.43 ± 107.49 pg/ml) compared to those without events (109.12 ± 86.54 pg/ml, P = 0.003).
• Multivariate analysis revealed that iPTH level was positively associated with CV events (OR = 1.3 per 50 pg/ml change, P = 0.02), independent of other factors like vascular disease history, vitamin D, calcium, phosphorus, and GFR.
• History of cardiovascular disease was the strongest predictor (OR = 5.9, P = 0.002).

Conclusions:

• Serum iPTH levels are significantly associated with an increased incidence of cardiovascular events in patients with moderate CKD.
• iPTH is an independent predictor of cardiovascular events in moderate CKD, irrespective of calcium and phosphorus levels.